Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 12/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | GALR3 | O60755 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30682488 | 1.00 | ATF4 (0.55) | ATF4NOTUMNPC1ATMRAB9A | |
| SCHEMBL22395373 | 0.92 | NOTUM (0.53) | ATF4NOTUMNPC1ATMRAB9A | |
| SCHEMBL30682480 | 0.92 | NOTUM (0.53) | ATF4NOTUMNPC1ATMRAB9A | |
| SCHEMBL22395301 | 0.89 | ATF4 (0.58) | ATF4GALR3 | |
| SCHEMBL22395370 | 0.89 | ATF4 (0.60) | ATF4 | |
| SCHEMBL21117016 | 0.85 | ATF4 (0.52) | ATF4ATM | |
| SCHEMBL22395375 | 0.85 | ATF4 (0.60) | ATF4 | |
| SCHEMBL22395368 | 0.83 | ATF4 (0.56) | ATF4NPC1RAB9A | |
| SCHEMBL19577497 | 0.83 | ATF4 (0.50) | ATF4 | |
| SCHEMBL30682450 | 0.83 | ATF4 (0.50) | ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240173307-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-30 | — | — | US | disclosed |
| EP-3704089-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20210393599-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-12-23 | — | — | US | disclosed |
| US-20210393599-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-12-23 | — | — | US | disclosed |
| EP-3704089-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240173307-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885NOTUM 4143/4885NPC1 1252/4885 |
| US-20210393599-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885NOTUM 4143/4885NPC1 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.